glucose, (beta-d)-isomer and linagliptin
glucose, (beta-d)-isomer has been researched along with linagliptin in 49 studies
Research
Studies (49)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 28 (57.14) | 24.3611 |
2020's | 21 (42.86) | 2.80 |
Authors
Authors | Studies |
---|---|
Friedrich, C; Mattheus, M; Metzmann, K; Pinnetti, S; Rose, P; Woerle, HJ | 1 |
Navarro, D | 1 |
Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 2 |
Aronson, R | 1 |
Woo, V | 1 |
Deeks, ED; Kim, ES | 1 |
Abdul-Ghani, M; Cersosimo, E; Defronzo, RA; Solis-Herrera, C; Triplitt, C | 1 |
Blüher, M; Kern, M; Klein, T; Klöting, N; Mark, M; Mayoux, E | 1 |
Broedl, UC; Gallwitz, B; Götz, S; Maldonado-Lutomirsky, M; Nordaby, M; Tinahones, FJ; Woerle, HJ | 1 |
Andersen, G; Falk, A; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
Scheen, AJ | 1 |
Friedrich, C; Glund, S; Mattheus, M; Rose, P; Runge, F | 1 |
Dey, J | 1 |
Lingvay, I | 1 |
Jain, RK | 1 |
Ahn, YB; Cha, SA; Ko, SH; Lim, TS; Park, YM; Song, KH; Yoo, KD; Yun, JS | 1 |
Gallwitz, B | 1 |
Elisaf, MS; Filippatos, TD; Rizos, CV | 1 |
Cheng, G; George, J; Haneda, M; Kawamori, R; Lee, C; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Suzaki, K | 1 |
DeFronzo, RA; Kohler, S; Lee, C | 1 |
Fawzy, MG; Mahrouse, MA; Moussa, BA | 2 |
George, J; Haneda, M; Kaku, K; Lee, C; Lee, G; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Tanaka, Y | 1 |
Brendel, M; Gerlitzki, C; Grube, A | 1 |
Abdullah, AM; Fakhre, NA; M Amin, KF | 1 |
Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K | 1 |
Del Parigi, A; Lee, C; Liu, D; Pratley, R; Tang, W | 1 |
Ferrannini, E; Katsiki, N; Mazidi, M; Ofori-Asenso, R | 1 |
Bgatova, NP; Dashkin, MV; Khotskina, AS; Klein, T; Klimontov, VV; Konenkov, VI; Korbut, AI; Muraleva, NA; Orlov, NB; Taskaeva, IS; Zavyalov, EL | 1 |
Beetz, N; Bertulis, J; Lang, B; Lee, J; Lingvay, I; Lippert, C; Loley, C; Manning, LS; Schuler-Metz, A; Sennewald, R; Terada, D | 1 |
Heilmann, C; Taniguchi, A; Watada, H; Yamamoto, F; Yamauchi, T; Yarush, L; Yasui, A | 1 |
Chuang, SM; Lee, CC; Liu, SC; Sun, FJ; Zeng, YH | 1 |
Chudasama, D; Kovil, R; Padhye, D; Raj, V; Saboo, B; Shah, K; Shaikh, N | 1 |
Alegete, P; Boodida, S; Vankalapati, KR | 1 |
Elmasry, MS; Hasan, MA; Hassan, WS; Merey, HA; Nour, IM | 1 |
Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y | 1 |
Elmasry, MS; Hassan, WS; Merey, HA; Nour, IM | 1 |
Anumolu, PD; Cvs, S; Gurrala, S; Raj, S | 1 |
Fushimi, Y; Ikeda, T; Kaku, K; Kaneto, H; Mune, T; Nakanishi, S; Nogami, Y; Obata, A; Obata, Y; Sanada, J; Shimoda, M; Yamasaki, Y | 1 |
Gupta, A; Jamwal, V; Khalse, M; Malhotra, P | 1 |
Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
Chenchula, S; Padmavathi, R; Varthya, SB | 1 |
Barkatestrong/Strong, H; Khaladkar, K; Mohan, B; Suryawanshi, S | 1 |
Abdelmalak, NS; Hammad, RW; Latif, R; Sanad, RA | 1 |
Lee, CC; Liu, JJ; Liu, SC; Sun, FJ; Zeng, YH | 1 |
Reviews
13 review(s) available for glucose, (beta-d)-isomer and linagliptin
Article | Year |
---|---|
Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2015 |
Glyxambi--a new combination for type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic | 2015 |
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucose; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Linagliptin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Medication Adherence; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Medication Adherence; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2018 |
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Trials
14 trial(s) available for glucose, (beta-d)-isomer and linagliptin
Article | Year |
---|---|
A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Germany; Glucose; Glucosides; Half-Life; Humans; Hypoglycemic Agents; Kidney; Linagliptin; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Purines; Quinazolines; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2013 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome | 2015 |
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pancreatitis; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2017 |
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome | 2017 |
Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
Topics: Administration, Oral; Adult; Area Under Curve; Benzhydryl Compounds; Biological Availability; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Female; Germany; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Linagliptin; Male; Metabolic Clearance Rate; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Solubility; Tablets; Therapeutic Equivalency | 2017 |
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Treatment Outcome | 2018 |
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome | 2018 |
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Linagliptin; Male; Middle Aged | 2019 |
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Topics: Aged; Arterial Pressure; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glucosides; Humans; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness | 2020 |
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Male; Medication Adherence; Metformin; Middle Aged; Therapeutic Equivalency; Young Adult | 2020 |
Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Renal Plasma Flow; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Prospective Studies; Pyrazoles; Treatment Outcome; Vildagliptin | 2022 |
Other Studies
22 other study(ies) available for glucose, (beta-d)-isomer and linagliptin
Article | Year |
---|---|
A report from the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) (September 15-19, 2014 - Vienna, Austria).
Topics: Animals; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus; Diabetic Nephropathies; Glucosides; Humans; Linagliptin | 2014 |
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Topics: Animals; Benzhydryl Compounds; Female; Glucose; Glucosides; Glycosides; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Linagliptin; Lipid Metabolism; Mice; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Linagliptin; Male; Membrane Transport Modulators; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
Topics: Benzhydryl Compounds; Canagliflozin; Drug Combinations; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets | 2018 |
Dissolution or disintegration - substitution of dissolution by disintegration testing for a fixed dose combination product.
Topics: Benzhydryl Compounds; Chemistry, Pharmaceutical; Drug Combinations; Glucosides; Linagliptin; Solubility | 2019 |
Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
Topics: Algorithms; Analysis of Variance; Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Tablets | 2019 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Glucosides; Glycated Hemoglobin; Humans; Linagliptin; Machine Learning; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucosides; Immunohistochemistry; Kidney Function Tests; Kidney Glomerulus; Linagliptin; Mice; Mice, Inbred Strains; Mice, Transgenic; Podocytes; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
Topics: Administration, Oral; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Metformin | 2020 |
Single-pill Combination of Empagliflozin and Linagliptin in Real World Indian Type 2 Diabetes Patient (GRID).
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; India; Linagliptin; Male; Prospective Studies | 2020 |
Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form.
Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Drug Stability; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Tablets | 2021 |
Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Compounding; Glucosides; Humans; Hypoglycemic Agents; Linagliptin | 2021 |
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes Mellitus, Type 2; Drainage; Female; Fournier Gangrene; Glucosides; Hospitals, Rural; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Obesity; Perineum; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2021 |
Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method.
Topics: Benzhydryl Compounds; Drug Compounding; Glucosides; Linagliptin; Spectrophotometry | 2021 |
Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin.
Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Glucosides; Limit of Detection; Linagliptin; Metformin; Reproducibility of Results | 2022 |
Application of experimental design in HPLC method optimization and robustness for the simultaneous determination of canagliflozin, empagliflozin, linagliptin, and metformin in tablet.
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2021 |
Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Combinations; Glucosides; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience.
Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Linagliptin; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2021 |
Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chitosan; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Pharmaceutical Preparations | 2022 |
Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin.
Topics: Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |